Ivermectin and Fenbendazole in Prostate Cancer — Joe Rogan and Dr. Mark Gordon Discuss a Case

A Prostate Cancer Case With Measurable Regression — Joe Rogan & Dr. Mark Gordon

In a one-minute cutout from The Joe Rogan Experience, Joe Rogan speaks with Dr. Mark Gordon about a prostate cancer case that immediately challenges the prevailing narrative around repurposed drugs. The exchange opens with Rogan joking that this is the kind of thing one “shouldn’t talk about publicly,” referencing the controversy surrounding ivermectin. Gordon plays along with the irony before Rogan points out that people are openly using it now.

Gordon then recounts a specific case involving a 76-year-old military veteran diagnosed with Gleason 7 prostate cancer, an intermediate-risk classification. According to Gordon, the patient took 12 mg of ivermectin daily for eight weeks, alongside fenbendazole. At twelve weeks, a specialized PET scan targeting prostate abnormalities reportedly showed no detectable cancer, while the patient’s PSA level dropped from 12.6 at diagnosis to 5.3. Rogan’s response is immediate: “That’s amazing.”
 

How Ivermectin and Fenbendazole Interact With Prostate Cancer Biology

Although the clip itself contains little mechanistic detail, the outcome Gordon describes aligns with existing scientific hypotheses around cancer metabolism and drug repurposing. Fenbendazole, a benzimidazole compound, disrupts microtubules and interferes with cell division, effects that disproportionately impact rapidly proliferating cancer cells. Preclinical research has also linked it to impaired glucose utilization and increased metabolic stress in tumors.

Ivermectin, meanwhile, has demonstrated effects in laboratory settings on mitochondrial function and cancer-relevant survival pathways, including PAK1 and WNT/β-catenin, which are frequently active in prostate cancer. Prostate tumors—particularly those classified as Gleason 7—are known for their metabolic adaptability, relying on multiple energy pathways to survive.

Used together, ivermectin and fenbendazole plausibly apply multi-axis metabolic pressure: one destabilizing structural and energetic processes tied to division, the other stressing mitochondrial stability and survival signaling. While this does not constitute clinical proof, it provides a coherent biological framework for why PSA reduction and imaging regression could occur in some patients.